As shown in several large clinical trials [4,5,6], visual outcomes in patients with macular neovascularization (MNV) secondary to AMD have significantly improved since the introduction of anti-vascular endothelial growth factor (VEGF), which is currently the first-line treatment for neovascular age-related macular degeneration (nAMD). This evidence concerns the gene VEGFA and wet macular degeneration.